Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to determine the efficacy and safety of DWJ1506 and DWJ1507 in the patients with dyslipidemia.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| DWJ1506 | Experimental |
| |
| DWJ1507 | Experimental |
| |
| DWC202011 | Active Comparator |
| |
| DWJ1177 | Active Comparator |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| DWJ1506 | Drug | DWJ1506 |
| |
| DWJ1507 |
| Measure | Description | Time Frame |
|---|---|---|
| LDL-C levels at week 8 | Change from baseline in LDL-C level at week 8 after administration of the IP | Week 8 |
Not provided
Not provided
Inclusion Criteria:
Exclusion Criteria:
6.Women who were of childbearing potential without contraception, pregnant, or breastfeeding
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D050171 | Dyslipidemias |
| ID | Term |
|---|---|
| D052439 | Lipid Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Drug |
DWJ1507 |
|
| DWC202011 | Drug | DWC202011 |
|
| DWJ1177 | Drug | DWC202011 |
|